ACT Accelerator, Therapeutics Partnership

The urgent need for effective therapeutics to limit the damage of COVID-19

The Access to COVID-19 Tools (ACT) Accelerator was launched in April 2020 by the World Health Organization and a range of global partners. The aim of this new collaboration is to make vaccines, diagnostics and therapeutics for COVID-19 accessible to everyone who needs them worldwide.

Unitaid is pleased to work alongside Wellcome as co-convenors of the Therapeutics Partnership in driving the work around development, manufacturing, procurement and deployment of treatments.

Given the close link between testing and treating in the COVID-19 response, Unitaid also participates in the Diagnostics Partnership, where it co-leads the work on ensuring market readiness. It is also engaged in activities for health systems strengthening as part of its work to ensure equitable access.

This page gives details of the different interventions that Unitaid is making to support the global efforts.

News releases:

UNITAID Is Fighting Against COVID-19 Through Collaboration

Global Goal: Unite for Our Future

Global Goal: Unite For Our Future*  | The Concert

Streamed live on 27 June 2020

*The campaign calls on world leaders, corporations, and philanthropists to commit the funds necessary to ensure there are enough tests, treatments, and vaccines to equitably reach everyone, everywhere in the world.

These funds will go to organizations that collectively make up the World Health Organization’s (WHO) ACT Accelerator, specializing in the development, production, and delivery of tests, treatments, and vaccines.


Coalition for Epidemic Preparedness Innovations (CEPI)

Gavi, the Vaccine Alliance

Wellcome Trust

The Therapeutics Accelerator

The Foundation for Innovative New Diagnostics (FIND)

The Global Fund

World Health Organization

For the latest news, follow the @UNITAID on Twitter

Media Contact:

Martin HARVEY | +41 79 249 35 29 |

Other enquiries click here

Sign Up for Unitaid Updates

  • This field is for validation purposes and should be left unchanged.